Oncternal Therapeutics

Investors · 1

VE

Vedanta CapitalNew York

$58.1M disclosed across 6 rounds · 2014–2018

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

TR

Transcode Therapeutics13 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.

RO

Robinhood11 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

ST

StockTwits8 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.

SI

Sionnatx8 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

RA

Radionetics8 shared keywordsRadionetics develops small molecule radiopharmaceuticals that target GPCRs, using radioisotope-tethered ligands to image and treat cancerous tumors as part of a theranostics precision medicine approach. The company serves the oncology field with therapeutic and diagnostic radiotherapeutics and is headquartered in San Diego's life sciences community.

DA

Day One Biopharmaceuticals7 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Companies competing with Oncternal Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.